Sanofi Closes In On A Pair Of Approval Firsts
Dupixent Approvals Expanded As Xenpozyme Gets CHMP Nod
The French major has secured a fourth approval, in eosinophilic esophagitis, for Dupixent, while the EMA is set to make Sanofi's enzyme replacement therapy, Xenpozyme, the first drug approved in Europe for acid sphingomyelinase deficiency.
You may also be interested in...
Almirall Throws Down Gauntlet To Dupixent With New Lebrikizumab Data
The Spanish group has revealed that eight out of ten atopic dermatitis patients treated with lebrikizumab maintained skin clearance after a year, which compares favorably with Sanofi and Regeneron's blockbuster Dupixent.
Keeping Track: US FDA Clears Vtama, But Not Bimekizumab Or Ycanth; Tibsovo Takes RTOR To Frontline AML Setting
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Sanofi Hits Rare Setback For Dupixent In Urticaria
The French major has hit a rare roadblock in the onward march of its anti-inflammatory blockbuster.